bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
Marcy l’Étoile, France – June 16th, 2025 – bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections. This strategic acquisition aims to enhance bioMérieux’s capabilities in next-generation sequencing (NGS) and rapid diagnostics, further solidifying its commitment to advancing healthcare and Antimicrobial Stewardship through innovative solutions.
Day Zero Diagnostics has developed groundbreaking technologies that integrate direct-from-whole-blood sample preparation, sequencing, and advanced ID/AST analytics. The sequencing-based rapid diagnostic in development by Day Zero Diagnostics can identify, within hours, both the species and the antibiotic resistance profile of a bacterial pathogen. Current approaches take 2-5 days to provide similar information. The assets to be acquired include NGS workflows, chemistries, reagents, as well as the bioinformatics pipeline and software.